The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1
Open accessAbstract
The mechanisms by which tumor microenvironments modulate nucleic acid-mediated innate immunity remain unknown. Here we identify the receptor TIM-3 as key in circumventing the stimulatory effects of nucleic acids in tumor immunity. Tumor-associated dendritic cells (DCs) in mouse tumors and patients with cancer had high expression of TIM-3. DC-derived TIM-3 suppressed innate immune responses through the recognition of nucleic acids by Toll-like receptors and cytosolic sensors via a galectin-9-independent mechanism. In contrast, TIM-3 interacted with the alarmin HMGB1 to interfere with the recruitment of nucleic acids into DC endosomes and attenuated the therapeutic efficacy of DNA vaccination and chemotherapy by diminishing the immunogenicity of nucleic acids released from dying tumor cells. Our findings define a mechanism whereby tumor microenvironments suppress antitumor immunity mediated by nucleic acids.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In line with this notion, the enzymatic degradation of extracellular nucleic acids considerably limits the immunogenicity of RCD [864, 875].”
From Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018. (2018) · cites this paper as [875]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
Pattern Recognition Receptors and Inflammation
Takeuchi, O., & Akira, S. (2010) · Cell · doi:10.1016/j.cell.2010.01.022 · Cited by 8,895
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056
Taking dendritic cells into medicine
Steinman, R. M., & Banchereau, J. (2007) · Nature · doi:10.1038/nature06175 · Cited by 2,162
The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity
Zhu, C., Anderson, A. C., Schubart, A., Xiong, H., Imitola, J., Khoury, S. J., Zheng, X. X., Strom, T. B., & Kuchroo, V. K. (2005) · Nature Immunology · doi:10.1038/ni1271 · Cited by 2,057
Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977
Immunosuppressive Strategies that are Mediated by Tumor Cells
Rabinovich, G. A., Gabrilovich, D. I., & Sotomayor, E. M. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141609 · Cited by 1,747
HMGB1 is a therapeutic target for sterile inflammation and infection
Andersson, U., & Tracey, K. J. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101323 · Cited by 1,437
Cited by
Sorted by citations
Items 801–838 of 838
Huang, F., Li, H., Miu, T., Chen, X., Wang, Y., Wang, Z., Zou, S., 覃理灵, & Zhi, Y. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.109417
Rewiring Dendritic Cell Immunity: The β-Catenin–TIM-3 Axis as a Target to Improve DC Cancer Vaccines
Fu, C., Ma, T., Zhou, L., Mi, Q., & Jiang, A. (2026) · Cancers · doi:10.3390/cancers18020201
Inhibitory receptor agonists: Emerging strategies in immune modulation
Adam, K. R., Suhail, A., Kuchroo, V. K., & Vignali, D. A. A. (2026) · The Journal of Experimental Medicine · doi:10.1084/jem.20241217
Vinot, P.-A. (2018) · theses.fr (ABES) · doi:10.70675/8d700747z53d5z4ad2z91fbz840e35448ca7
Strategies of Cancer Immunotherapy : Model of Triple Negative Breast Cancer
Kishi, M. (2019) · theses.fr (ABES) · doi:10.70675/51302a51z120az4319z9cebzc7a90f0976ce
Rôle de la Neuropiline-1 dans les fonctions effectrices des lymphocytes T CD8 antitumoraux
Leclerc, M. (2018) · theses.fr (ABES) · doi:10.70675/13aee211zad7bz4b07z9a5fz29b15750d99c
Molecular and cellular basis of phosphatidylserine receptors mediated flavivirus infection
Dejarnac, O. (2017) · theses.fr (ABES) · doi:10.70675/77142d81ze3a4z497cz85c3zcfd1edd1ce35
Naour, J. L. (2022) · theses.fr (ABES) · doi:10.70675/ad2bd68az83cdz4738zb39fz6a66ef3080d3
TIM-3 in Cardiovascular Disease
Yousif, L. I. E., Sijtema, A. G., Chevalier, M. J., de Boer, R. A., & Meijers, W. C. (2026) · Current Heart Failure Reports · doi:10.1007/s11897-026-00755-y
Ferron, E. (2024) · theses.fr (ABES) · doi:10.70675/f7ee5cbez3975z4d1fz908cz5a84a3a5f736
Trioën, C. (2024) · theses.fr (ABES) · doi:10.70675/7c132518z8997z4d01z8084z87c06a661e5a
Regulation of Immune Checkpoints: From Molecular Mechanisms to Clinical Therapies
Ge, Q., Yu, L., Lu, J., Anwaier, A., Xiao, X., Chen, Y., Ye, D., Zhang, H., Xu, W., & Dai, W. (2026) · MedComm · doi:10.1002/mco2.70771
Advancements in Immune Checkpoint-Based Immunotherapy for Triple-Negative Breast Cancer
Wei, D., Zhang, Y., Wu, Y. S., Ren, L., & He, Q. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48060615
When lipids silence immunity: Dendritic cell death in MASLD-associated HCC
Kocheise, L., & Schneider, K. M. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.06.008
Tim-3 Sustains Tumor Treg Stability and Function, Limiting Checkpoint Blockade Therapy Efficacy
Banerjee, H., Onyekachi, O. V., Nieves-Rosado, H. M., Murter, B., Kulkarni, A., Pandey, S., Cardona, E., Dougherty, J. E., Li, H., Upadhyay, P., et al. (2026) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-25-0687
The metabolic roles of immune checkpoint molecules
Wang, Y., Wang, J., Dan, S., Zheng, J., Lu, Y., & Xia, F. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag030
Alimohammadi, M., Mirnejad, A. M., Farahani, N., Hedayati, N., & Hushmandi, K. (2026) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-026-06566-x
Targeting Immune Checkpoint Proteins in Cancer Therapy and the Potential of RNAi-Based Immunotherapy
Wang, K. K., & Yu, A. (2026) · Pharmaceuticals · doi:10.3390/ph19081212
Wang, X., Peng, W., Ni, M., & Li, J. (2026) · Journal of Functional Foods · doi:10.1016/j.jff.2026.107459
Su, P., Zhang, Y., Yu, T., 王元宇, 牟一平, & Jin, W. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.117338
Cancer Immunotherapy: Therapeutic Limitations and Next-Generation Precision Strategies
Ko, D., Park, S., Nam, K.-H., Choi, J., & Lee, K. (2026) · Immune Network · doi:10.4110/in.2026.26.e31
Huang, Y., Li, J., Qin, Y., Qie, B., Wang, Q., Liu, C., & Zhu, Y. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179308
Pong, L., Hassanudin, S., Tham, S. K., Manickam, R., Wong, C., Poh, K., & Poh, C. L. (2026) · International Journal of Oncology · doi:10.3892/ijo.2026.5936
Molecular Architecture and Clinical Landscape of Immune Checkpoint Receptors and Ligands
Czosnek, M., Sowa, A., Rolek, Ł., Grywalska, E., Mertowski, S., & Mertowska, P. (2026) · Antibodies · doi:10.3390/antib15050084
Anikeeva, O. S., Маркова, Е. В., Гольдина, И. А., Серенко, Е. В., Шушпанова, Т. В., & Владимирович, С. И. (2026) · Успехи геронтологии · doi:10.34922/ae.2026.39.4.013
Harnessing tumor immune checkpoints for autoimmune disease therapeutics
Yang, H., Zhang, J., Wu, Y., Xie, N., & Shen, G. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1725372
Kumar, S., Shubham, Mishra, M., Kumar, R., & Sen, P. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-026-03227-x
Liang, L.-K., Ye, Q., Li, J., Shi, L.-Y., Wang, S.-P., Liang, W.-J., Chen, A., & Feng, G. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-026-01947-x
Seol, S.-I., Kim, J., Davaanyam, D., Park, S., Lee, E.-H., Han, P.-L., Kim, T.-K., & Lee, J.-K. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27198681
罗家镏, Zhang, P., Gu, S., Lin, Z., Wu, Y., & Tang, Z. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18101343
Metadata
- Authors
- Chiba, S., Baghdadi, M., Akiba, H., Yoshiyama, H., Kinoshita, I., Dosaka-Akita, H., Fujioka, Y., Ohba, Y., Gorman, J. V., Colgan, J. D., Hirashima, M., Uede, T., Takaoka, A., Yagita, H., & Jinushi, M.
- Affiliations
- Hokkaido University (JP)
- Juntendo University (JP)
- University of Iowa (US)
- Kagawa University (JP)
- Corresponding author
- Jinushi, Masahisa
- ORCID
- Venue
- Nature Immunology
- Published
- 2012-07-29
- Volume
- 13
- Issue
- 9
- Pages
- 832-842
- ISSN
- 1529-2908 (ISSN-L)
- 1529-2916
- PMC
- PMC3622453
- OpenAlex
- W2112400160
- Cited by
- 838
- References
- 50
- Citations by year
- 2026: 40 · 2025: 53 · 2024: 81 · 2023: 82 · 2022: 83 · 2021: 80 · 2020: 65 · 2019: 63 · 2018: 56 · 2017: 48 · 2016: 53 · 2015: 41 · 2014: 39 · 2013: 39 · 2012: 15
- FWCI
- 18.74
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Immunology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion)
- Hokkaido University Collection of Scholarly and Academic Papers (Hokkaido University) (submittedVersion)
- Funders
- Japan Society for the Promotion of Science (23590534, 23591132, 23501283, 22590360, 23390090, 22591098, 22240089, 23659196, 21390113)
- National Institute of Allergy and Infectious Diseases (R01AI093737, R01AI067489)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- TIM-3, HMGB1, tumor-associated dendritic cells, nucleic acid sensing, innate immunity, tumor microenvironment, Toll-like receptors, galectin-9, DNA vaccine, chemotherapy, antitumor immunity, alarmins
- MeSH terms
- Hepatitis A Virus Cellular Receptor 2, Animals, Dendritic Cells, Enzyme-Linked Immunosorbent Assay, Flow Cytometry, Humans, Immunity, Innate, Immunologic Surveillance, Mice, Inbred C57BL, Microscopy, Fluorescence, Neoplasms, Nucleic Acids, Receptors, Virus, Immunoblotting, Microscopy, Confocal, Reverse Transcriptase Polymerase Chain Reaction, HMGB1 Protein, Receptors, Pattern Recognition, Mice, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
